Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Sysa Shah, Polina ^a   Xu, Yi ^a   Guo, Xin ^a   Belmonte, Frances ^a   Kang, Byunghak ^a   Bedja, Djahida ^a   Pin, Scott ^a   Tsuchiya, Noriko ^a,b   Gabrielson, Kathleen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HEAT SHOCK PROTEIN; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; LAPATINIB; MESSENGER RNA; MYOSIN HEAVY CHAIN BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P85; PROTEIN S6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; ERBB2 GENE; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEART WEIGHT; HYPERTROPHIC CARDIOMYOPATHY; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TRANSLATION INITIATION;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY, HYPERTROPHIC; CELL SURVIVAL; ELECTROPHYSIOLOGICAL PROCESSES; GENE EXPRESSION; ISOPROTERENOL; MALE; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; ORGAN SIZE; ORGAN SPECIFICITY; PROTEIN BIOSYNTHESIS; QUINAZOLINES; RATS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84865003452     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042805     Document Type: Article

References (74)

1. Baselga J, ((2001)) Clinical trials of Herceptin(R) (trastuzumab). Eur J Cancer 37 (Suppl 1):: 18--24.
2. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, et al. ((1996)) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14(3):: 737--744.
3. McKeage K, Perry CM, ((2002)) Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62(1):: 209--243.
4. Negro A, Brar BK, Lee KF, ((2004)) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:: 1--12.
5. Lee KF, Simon H, Chen H, Bates B, Hung MC, et al. ((1995)) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555):: 394--398.
6. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA, ((2002)) Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 8(8):: 850--855.
7. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, et al. ((2002)) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):: 459--465.
8. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, et al. ((2002)) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99(13):: 8880--8885.
9. Behr TM, Behe M, Wormann B, ((2001)) Trastuzumab and breast cancer. N Engl J Med 345(13):: 995--996.
10. Gabrielson K, Bedja D, Pin S, Tsao A, Gama L, et al. ((2007)) Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res 67(4):: 1436--1441.
11. Sahn DJ, DeMaria A, Kisslo J, Weyman A, ((1978)) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58(6):: 1072--1083.
12. Daugherty A, Rateri D, Hong L, Balakrishnan A, ((2009)) Measuring blood pressure in mice using volume pressure recording, a tail-cuff method. J Vis Exp (27).
13. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, et al. ((2002)) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277(25):: 22896--22901.
14. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, et al. ((2000)) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Embo Journal 19(11):: 2537--2548.
15. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, et al. ((2002)) Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22(8):: 2799--2809.
16. Fenton TR, Gout IT, ((2011)) Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43(1):: 47--59.
17. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, et al. ((1994)) Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371(6500):: 762--767.
18. Sadoshima J, Izumo S, ((1995)) Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res 77(6):: 1040--1052.
19. Boluyt MO, Zheng JS, Younes A, Long X, O'Neill L, et al. ((1997)) Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ Res 81(2):: 176--186.
20. Boluyt MO, Li ZB, Loyd AM, Scalia AF, Cirrincione GM, et al. ((2004)) The mTOR/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Cardiovasc Drugs Ther 18(4):: 257--267.
21. Rohrbach S, Muller-Werdan U, Werdan K, Koch S, Gellerich NF, et al. ((2005)) Apoptosis-modulating interaction of the neuregulin/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. J Mol Cell Cardiol 38(3):: 485--493.
22. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, et al. ((2004)) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44(11):: 2231--2238.
23. Rohrbach S, Niemann B, Silber RE, Holtz J, ((2005)) Neuregulin receptors erbB2 and erbB4 in failing human myocardium - depressed expression and attenuated activation. Basic Res Cardiol 100(3):: 240--249.
24. Sakamoto M, Minamino T, Toko H, Kayama Y, Zou Y, et al. ((2006)) Upregulation of heat shock transcription factor 1 plays a critical role in adaptive cardiac hypertrophy. Circ Res 99(12):: 1411--1418.
25. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, et al. ((2009)) Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 28(42):: 3689--3701.
26. Romhilt DW, Estes EH Jr, ((1968)) A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J 75(6):: 752--758.
27. Okin PM, Devereux RB, Fabsitz RR, Lee ET, Galloway JM, et al. ((2002)) Quantitative assessment of electrocardiographic strain predicts increased left ventricular mass: the Strong Heart Study. J Am Coll Cardiol 40(8):: 1395--1400.
28. Martens UM, ((2009)) Small Molecules in Oncology, Springer.
29. Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, et al. ((2008)) Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 73(2):: 338--348.
30. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, et al. ((2009)) Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 53(4):: 594--598.
31. Uray IP, Connelly JH, Frazier O, Taegtmeyer H, Davies PJ, ((2001)) Altered expression of tyrosine kinase receptors Her2/neu and GP130 following left ventricular assist device (LVAD) placement in patients with heart failure. J Heart Lung Transplant 20(2):: 210.
32. Perik PJ, de Vries EG, Gietema JA, van der Graaf WT, Smilde TD, et al. ((2007)) Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 9(2):: 173--177.
33. Naga Prasad SV, Duan ZH, Gupta MK, Surampudi VS, Volinia S, et al. ((2009)) Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem 284(40):: 27487--27499.
34. Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, et al. ((2010)) Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87(4):: 656--664.
35. Doggen K, Ray L, Mathieu M, Mc Entee K, Lemmens K, et al. ((2009)) Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. J Mol Cell Cardiol 46(1):: 33--38.
36. Rohrbach S, Yan X, Weinberg EO, Hasan F, Bartunek J, et al. ((1999)) Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 100(4):: 407--412.
37. Reiss K, Cheng W, Ferber A, Kajstura J, Li P, et al. ((1996)) Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci U S A 93(16):: 8630--8635.
38. McMullen JR, Shioi T, Huang WY, Zhang L, Tarnavski O, et al. ((2004)) The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 279(6):: 4782--4793.
39. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, et al. ((2003)) Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 100(21):: 12355--12360.
40. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, et al. ((2005)) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115(8):: 2108--2118.
41. Taniyama Y, Ito M, Sato K, Kuester C, Veit K, et al. ((2005)) Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. J Mol Cell Cardiol 38(2):: 375--385.
42. Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, et al. ((2003)) Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci U S A 100(14):: 8281--8286.
43. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, et al. ((1998)) ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18(9):: 5042--5051.
44. Yarden Y, Sliwkowski MX, ((2001)) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):: 127--137.
45. Olayioye MA, Neve RM, Lane HA, Hynes NE, ((2000)) The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19(13):: 3159--3167.
46. Sweeney C, Fambrough D, Huard C, Diamonti AJ, Lander ES, et al. ((2001)) Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem 276(25):: 22685--22698.
47. Sweeney C, Carraway KL 3rd ((2000)) Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 19(49):: 5568--5573.
48. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE, ((1999)) ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274(24):: 17209--17218.
49. Bersell K, Arab S, Haring B, Kuhn B, ((2009)) Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138(2):: 257--270.
50. Esparis-Ogando A, Diaz-Rodriguez E, Pandiella A, ((1999)) Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochem J 344 Pt 2:: 339--348.
51. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, et al. ((2004)) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6(3):: 251--261.
52. McConnell BK, Fatkin D, Semsarian C, Jones KA, Georgakopoulos D, et al. ((2001)) Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res 88(4):: 383--389.
53. Muthuchamy M, Pieples K, Rethinasamy P, Hoit B, Grupp IL, et al. ((1999)) Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res 85(1):: 47--56.
54. Prabhakar R, Petrashevskaya N, Schwartz A, Aronow B, Boivin GP, et al. ((2003)) A mouse model of familial hypertrophic cardiomyopathy caused by a alpha-tropomyosin mutation. Mol Cell Biochem 251(1-2):: 33--42.
55. Hershberger RE, Cowan J, Morales A, Siegfried JD, ((2009)) Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2(3):: 253--261.
56. Ho CY, ((2010)) Hypertrophic cardiomyopathy. Heart Fail Clin 6(2):: 141--159.
57. de Bakker JM, van Rijen HM, ((2006)) Continuous and discontinuous propagation in heart muscle. J Cardiovasc Electrophysiol 17(5):: 567--573.
58. Uzzaman M, Honjo H, Takagishi Y, Emdad L, Magee AI, et al. ((2000)) Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension. Circ Res 86(8):: 871--878.
59. Ripplinger CM, Li W, Hadley J, Chen J, Rothenberg F, et al. ((2007)) Enhanced transmural fiber rotation and connexin 43 heterogeneity are associated with an increased upper limit of vulnerability in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 101(10):: 1049--1057.
60. Wolf CM, Moskowitz IP, Arno S, Branco DM, Semsarian C, et al. ((2005)) Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc Natl Acad Sci U S A 102(50):: 18123--18128.
61. Fineschi V, Silver MD, Karch SB, Parolini M, Turillazzi E, et al. ((2005)) Myocardial disarray: an architectural disorganization linked with adrenergic stress? Int J Cardiol 99(2):: 277--282.
62. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, et al. ((2001)) Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation 104(12):: 1380--1384.
63. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, et al. ((2001)) Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 344(24):: 1823--1831.
64. Oliveira SM, Ehtisham J, Redwood CS, Ostman-Smith I, Blair EM, et al. ((2003)) Mutation analysis of AMP-activated protein kinase subunits in inherited cardiomyopathies: implications for kinase function and disease pathogenesis. J Mol Cell Cardiol 35(10):: 1251--1255.
65. Di Mauro S, Tanji K, Hirano M, ((2007)) LAMP-2 deficiency (Danon disease). Acta Myol 26(1):: 79--82.
66. Yang Z, Funke BH, Cripe LH, Vick GW 3rd, Mancini-Dinardo D, et al ((2010)) LAMP2 microdeletions in patients with Danon disease. Circ Cardiovasc Genet 3(2):: 129--137.
67. Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, et al. ((2011)) Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med 13(7):: 625--631.
68. Efthimiou J, McLelland J, Betteridge DJ, ((1986)) Short PR intervals and tachyarrhythmias in Fabry's disease. Postgrad Med J 62(726):: 285--287.
69. Yokoyama A, Yamazoe M, Shibata A, ((1987)) A case of heterozygous Fabry's disease with a short PR interval and giant negative T waves. Br Heart J 57(3):: 296--299.
70. Jimenez J, Tardiff JC, ((2011)) Abnormal heart rate regulation in murine hearts with familial hypertrophic cardiomyopathy-related cardiac troponin T mutations. Am J Physiol Heart Circ Physiol 300(2):: H627--635.
71. Knollmann BC, Blatt SA, Horton K, de Freitas F, Miller T, et al. ((2001)) Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. J Biol Chem 276(13):: 10039--10048.
72. Ciampi Q, Betocchi S, Lombardi R, Manganelli F, Storto G, et al. ((2002)) Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. Journal of the American College of Cardiology 40(2):: 278--284.
73. Abraham TP, Jones M, Kazmierczak K, Liang HY, Pinheiro AC, et al. ((2009)) Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice. Cardiovasc Res 82(1):: 84--92.
74. Georgakopoulos D, Christe ME, Giewat M, Seidman CM, Seidman JG, et al. ((1999)) The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat Med 5(3):: 327--330.